Skip to content
PeptideAgent

Telehealth providers in Connecticut

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

Telehealth prescribing is allowed in Connecticut, including asynchronous care. What Connecticut requires of telehealth prescribers and pharmacies, plus verified listings.

Connecticut at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified telehealth providers serving Connecticut

No verified telehealth providers serving Connecticut are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Telehealth prescribing rules in Connecticut

Section 19a-906 defines telehealth to include synchronous interactions, asynchronous store and forward transfers, and remote patient monitoring, and requires a telehealth provider to meet the same standard of care as in-person care, have access to the patient's relevant medical history, and obtain consent. The statute bars telehealth prescribing of schedule I, II, and III controlled substances except narrow non-opioid psychiatric and substance use disorder cases; peptides in this database are not controlled, so that limit does not affect GLP-1 or compounded peptide prescriptions. The temporary authorization in section 19a-906 that let certain out-of-state providers treat Connecticut patients ran through June 30, 2025, so a prescriber now generally needs a Connecticut license. Because asynchronous care is expressly part of the definition, a non-controlled prescription may follow an asynchronous evaluation that meets the standard of care. [2] [3]

Compounded GLP-1 access in Connecticut

Because compounded GLP-1 injections are sterile preparations, an out-of-state pharmacy shipping them to Connecticut must have an approved sterile compounding addendum under section 20-633b in addition to its nonresident registration. [5] [6] [10]

Research use only sellers in Connecticut

Only Connecticut-licensed pharmacies and registered nonresident pharmacies may dispense prescription drugs to Connecticut patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Connecticut's sterile compounding approval system. Connecticut law also bars the sale directly: under the Connecticut Food, Drug and Cosmetic Act, section 21a-110 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has been approved under section 355 of the federal act or, for a drug not subject to the federal act, a state application has been filed with the Commissioner of Consumer Protection. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. 42-110a and following) against sellers of research-grade GLP-1s, including a 2025 settlement with an online distributor and a May 2026 settlement under which an international online trade platform agreed to stop GLP-1 sales to US consumers and remove such listings. The same May 2026 announcement included a settlement with a medical spa that stopped advertising and prescribing compounded semaglutide and tirzepatide. [5] [8] [11] [12]

How to check a telehealth provider in Connecticut

  1. Confirm the prescriber is licensed or registered to treat patients located in Connecticut; the telehealth rules above explain what Connecticut requires. [2] [3]
  2. Ask which pharmacy will fill the prescription and check it in the Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division) license lookup. [1] [4] [5] [6] [7] [9]
  3. Get the full price in writing first: consult fees, membership fees, and the medication itself.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Connecticut. [5] [8] [11] [12]

Common questions in Connecticut

Does Connecticut allow asynchronous telehealth prescribing for GLP-1 drugs?

Yes. Section 19a-906 defines telehealth to include asynchronous store and forward transfers, and semaglutide and tirzepatide are not controlled substances, so a Connecticut-licensed provider may prescribe them after an evaluation that meets the in-person standard of care and includes access to your medical history. [2]

Can an out-of-state telehealth doctor still treat me in Connecticut?

Generally only with a Connecticut license. The temporary out-of-state authorization in section 19a-906 ran through June 30, 2025. Check the provider on the Department of Public Health license lookup before paying. [2] [3]

What does an out-of-state pharmacy need to send me injectable compounded peptides in Connecticut?

A nonresident pharmacy registration under section 20-627 plus an approved sterile compounding addendum under section 20-633b, which requires proof of a passed home-state inspection and written approval from the Department of Consumer Protection and the Commission of Pharmacy before any sterile product is shipped. [5] [6]

All peptide legal questions for Connecticut

Sources

  1. [1]Connecticut Commission of Pharmacy, Department of Consumer Protection
  2. [2]Connecticut General Statutes section 19a-906, Telehealth services
  3. [3]Connecticut General Statutes chapter 368ll (current text of section 19a-906)
  4. [4]Connecticut General Statutes chapter 400j, Pharmacy
  5. [5]Connecticut General Statutes section 20-627, Nonresident pharmacy registration
  6. [6]Connecticut General Statutes section 20-633b, Sterile compounding pharmacies
  7. [7]Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, Sterile compounding pharmacies (standards in section 20-576-66, adopted effective July 12, 2011), accessed 2026-09-22
  8. [8]Connecticut General Statutes chapter 418 (Connecticut Food, Drug and Cosmetic Act), section 21a-110, New drugs, accessed 2026-09-22
  9. [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts
  12. [12]Connecticut Attorney General: Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales Nationwide (May 6, 2026)